Jotbody is a biotech company dedicated to developing and producing single domain antibody (sdAb). SdAb, the smallest antigen-binding fragment known in nature, holds many advantages over conventional antibodies, thus stealing the show as the ideal tool for developing diagnostic kits and therapeutics. High-cost production, owning to complicated animal farming, is currently restraining the success of sdAb.
Jotbody was the first to establish and validate an sdAb discovery platform based on a local small shark species. Our platform allows large-scale production of superior sdAb in a time- and cost-effective manner. Jotbody holds four patents, and our innovation has been published in peer-reviewed scientific journals. Jotbody has a globally recognised board of directors with well-documented experience in biotherapeutics development and entrepreneurship, and is developing sdAb products for several clients. SdAb will revolutionise the current clinical settings, and Jotbody aims to contribute to the development of a new wave of therapeutics.
Team members
Adviser: Dr Shi Jiahai (Adjunct Professor, Dept. of Biomedical Sciences, CityU
Dr Wei Likun (Alumnus, Dept. of Biomedical Sciences, CityU)
Dr Yang Naibo (Stanford University)
Dr Lin Xiangqian (The Wharton School)
* Person-in-charge
(Info based on the team's application form)
Achievement
2. CityU HK Tech 300 Seed Fund (2021)
3. Winning Prize, The 13th China (Shenzhen) Innovation and Entrepreneurship Competition, Shenzhen-Hong Kong-Macao University Preliminary Competition (2021)
4. Semi-final Team Promotion Award, The 11th China (Shenzhen) Innovation and Entrepreneurship Competition (2019)